Joined AstraZeneca in 2010 and led the development of some of the Company’s most innovative cancer therapies. She was Senior Vice-President and Head of Research and Early Development, Oncology R&D, and had overseen the progression of seven programmes into Phase III trials, with four new medicines now approved around the world: Lynparza (olaparib), the first-in-class PARP inhibitor approved in ovarian, breast, prostate and pancreatic cancers; Tagrisso (osimertinib), a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (TKI) approved in lung cancer; Orpathys (savolitinib), an oral, potent and highly selective MET TKI approved in China for non-small cell lung cancer patients with MET exon 14 skipping alterations; and Koselugo (selumetinib), an inhibitor of mitogen-activated protein kinase  approved in paediatric patients with neurofibromatosis type 1 with plexiform neurofibromas.